These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 17301106)

  • 1. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2007 Jul; 66(7):921-6. PubMed ID: 17301106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
    Radstake TR; Svenson M; Eijsbouts AM; van den Hoogen FH; Enevold C; van Riel PL; Bendtzen K
    Ann Rheum Dis; 2009 Nov; 68(11):1739-45. PubMed ID: 19019895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
    Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
    Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
    Bartelds GM; Krieckaert CL; Nurmohamed MT; van Schouwenburg PA; Lems WF; Twisk JW; Dijkmans BA; Aarden L; Wolbink GJ
    JAMA; 2011 Apr; 305(14):1460-8. PubMed ID: 21486979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Wolbink GJ; de Vries N; Tak PP; Dijkmans BA; Crusius JB; van der Horst-Bruinsma IE
    Arthritis Rheum; 2009 Aug; 60(8):2541-2. PubMed ID: 19644871
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
    Pascual-Salcedo D; Plasencia C; Ramiro S; Nuño L; Bonilla G; Nagore D; Ruiz Del Agua A; Martínez A; Aarden L; Martín-Mola E; Balsa A
    Rheumatology (Oxford); 2011 Aug; 50(8):1445-52. PubMed ID: 21427177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key findings towards optimising adalimumab treatment: the concentration-effect curve.
    Pouw MF; Krieckaert CL; Nurmohamed MT; van der Kleij D; Aarden L; Rispens T; Wolbink G
    Ann Rheum Dis; 2015 Mar; 74(3):513-8. PubMed ID: 24326008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
    J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.
    Bennett AN; Peterson P; Zain A; Grumley J; Panayi G; Kirkham B
    Rheumatology (Oxford); 2005 Aug; 44(8):1026-31. PubMed ID: 15870150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.
    Vogelzang EH; Kneepkens EL; Nurmohamed MT; van Kuijk AW; Rispens T; Wolbink G; Krieckaert CL
    Ann Rheum Dis; 2014 Dec; 73(12):2178-82. PubMed ID: 25115447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
    Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
    Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.
    Weinblatt ME; Keystone EC; Furst DE; Kavanaugh AF; Chartash EK; Segurado OG
    Ann Rheum Dis; 2006 Jun; 65(6):753-9. PubMed ID: 16308341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
    Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
    J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.